1 |
Yang H, Xue M, Su P, Zhou Y, Li X, Li Z, Xia Y, Zhang C, Fu M, Zheng X, Luo G, Wei T, Wang X, Ding Y, Zhu J, Zhuang T. RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer. J Exp Clin Cancer Res 2022;41:364. [PMID: 36581998 DOI: 10.1186/s13046-022-02576-y] [Reference Citation Analysis]
|
2 |
Hashemi M, Mirzaei S, Barati M, Hejazi ES, Kakavand A, Entezari M, Salimimoghadam S, Kalbasi A, Rashidi M, Taheriazam A, Sethi G. Curcumin in the treatment of urological cancers: Therapeutic targets, challenges and prospects. Life Sci 2022;309:120984. [PMID: 36150461 DOI: 10.1016/j.lfs.2022.120984] [Reference Citation Analysis]
|
3 |
Hwang HH, Chang KH, Choi YY, Jung I, Kang I, Choi Y, O MJ, Cho C, Kang P, Park H, Jang C, Lee S. Selective Anticancer Effects by Oxyclozanide in Triple-Negative Breast Cancer Expressing S100A9. DTT 2022;1:1-11. [DOI: 10.58502/dtt.22.003] [Reference Citation Analysis]
|